Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Opportunities in In Situ Hybridization

This article was originally published in Start Up

Executive Summary

In-situ hybridization (ISH) is a powerful method of genetic testing. But it has not yet found a place in the clinical laboratory. In addition to technical, patent and regulatory obstacles, participants will confront a fragmented market composed currently of high-priced, low-volume tests. Many scientists believe ISH will have an important role in the clinical laboratory, while others see it mostly as an interim technology likely to be superseded by easier-to-use DNA chips.

You may also be interested in...



Vysis Preps For Prime Time

Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.

What’s Next? Five Things To Look Out For In December

Generics Bulletin previews the most noteworthy and anticipated events for December 2023.

Member States Want Action Over High-Risk IVDs and Eudamed Medical Device Database

After some 10 years of the implementation of the EU’s Medical Device and IVD Regulations being an annual agenda item at December Council of the EU meetings, the scale of problems remains the same.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel